Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester disease.

Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm derived from the macrophage/dendritic cell lineage and harbors the BRAFV600E mutation in 50–60% of patients [1]. The U.S. Food and Drug ...